Xiaomei Qu
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Role not yet determined Is this you? Add your title
Also affiliated: Nanjing Tech University (2025); State Street (United States) (1999); Nanyang Technological University (2011–2017); Wuhan University of Technology (2024); Chinese Academy of Sciences (2025); Sichuan University (2008–2010); State Ethnic Affairs Commission (2019–2025); University of Mississippi Medical Center (1999); Sichuan Agricultural University (2025); Beijing University of Technology (2025); Nanyang Institute of Technology (2025); Microbiology Institute of Shaanxi (1994); Wuhan Union Hospital (2014); Center for Excellence in Molecular Plant Sciences (2025); First Hospital of China Medical University (2023–2024); Obstetrics and Gynecology Hospital of Fudan University (2009–2022); Union Hospital (2014); University of Chinese Academy of Sciences (2025); Shandong Jianzhu University (2024); Huazhong University of Science and Technology (2009–2025); Southwest Minzu University (2010–2025); Shandong Institute of Business and Technology (2025); Vanderbilt University Medical Center (2017); China Medical University (2023–2025)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Xiaomei Qu's research program focuses on the application of advanced therapeutic strategies for locally advanced rectal cancer. A significant area of investigation involves neoadjuvant short-course radiotherapy in combination with camrelizumab and chemotherapy. Qu has contributed to multicenter randomized phase III trials evaluating these treatment regimens, with early outcomes published in peer-reviewed literature. This work explores the efficacy and safety of these combined approaches compared to standard chemoradiotherapy protocols. Qu's research network includes collaborators from the National Center for Toxicological Research, with whom they have co-authored publications. With a career h-index of 13 and over 93 publications, Qu's work contributes to the field of cancer treatment and pharmacology.
Metrics
- h-index: 13
- Publications: 93
- Citations: 879
Selected Publications
-
Background Mutation Frequencies in TK6 and L5178Y Cells: Implications for Error‐Corrected Sequencing (2025)
Collaboration Network
Top Collaborators
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
- Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing
Similar Researchers
Based on overlapping research topics